MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in Nature Biotechnology last month, the latest advance from the institute centered on an automated, closed system capable of producing clinical-grade therapeutic proteins in three days.
Christopher Love, who led the project, says his Integrated Scalable Cyto-Technology (InSCyT) system brings the field closer to a vision of regionalized, small-footprint production.
“With some added containment and controlled space these systems we’ve built would let you establish small, efficient facilities,” Love told BioCentury. “You could consider manufacturing even at the level of a hospital or a pharmacy.”
Love, who is a professor of chemical engineering at the Massachusetts Institute of Technology, thinks the system could be useful for responding to viral outbreaks and battlefield needs, where “fast, agile and flexible manufacturing is the key.” It could also be a good fit for a variety of personalized medicine applications, or to improve the efficiency of process development.
“For a biopharma, this opens up opportunities to more rapidly test products during discovery all the way to the other end, to make the right-sized batch for a rare disease or personalized medicine,” said Love.
The work follows a series of papers from MIT scientists on microfluidic-based bioreactors for protein production, including a 2015 study in Lab on a Chip by Love and Rajeev Ram, a professor of electrical engineering at MIT.
In Nature Communications in 2016, Ram and Timothy